Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients
Currently, there is no specific immunosuppressive protocol for hepatitis C (HCV)-positive renal transplants recipients. Thus, the aim of this study was to evaluate the conversion effect to everolimus (EVR) on HCV in adult kidney recipients. This is an exploratory single-center, prospective, randomiz...
Saved in:
| Published in: | Brazilian Journal of Nephrology Vol. 40; no. 2; pp. 143 - 150 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Brazil
Sociedade Brasileira de Nefrologia
01-04-2018
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Currently, there is no specific immunosuppressive protocol for hepatitis C (HCV)-positive renal transplants recipients. Thus, the aim of this study was to evaluate the conversion effect to everolimus (EVR) on HCV in adult kidney recipients.
This is an exploratory single-center, prospective, randomized, open label controlled trial with renal allograft recipients with HCV-positive serology. Participants were randomized for conversion to EVR or maintenance of calcineurin inhibitors.
Thirty patients were randomized and 28 were followed-up for 12 months (conversion group, Group 1 =15 and control group, Group 2 =13). RT-PCR HCV levels reported in log values were comparable in both groups and among patients in the same group. The statistical analysis showed no interaction effect between time and group (p value G*M= 0.852), overtime intra-groups (p-value M=0.889) and between group (p-value G=0.286). Group 1 showed a higher incidence of dyslipidemia (p=0.03) and proteinuria events (p=0.01), while no difference was observed in the incidence of anemia (p=0.17), new onset of post-transplant diabetes mellitus (p=1.00) or urinary tract infection (p=0.60). The mean eGFR was similar in both groups.
Our study did not show viral load decrease after conversion to EVR with maintenance of antiproliferative therapy. |
|---|---|
| AbstractList | ABSTRACT Introduction: Currently, there is no specific immunosuppressive protocol for hepatitis C (HCV)-positive renal transplants recipients. Thus, the aim of this study was to evaluate the conversion effect to everolimus (EVR) on HCV in adult kidney recipients. Method: This is an exploratory single-center, prospective, randomized, open label controlled trial with renal allograft recipients with HCV-positive serology. Participants were randomized for conversion to EVR or maintenance of calcineurin inhibitors. Results: Thirty patients were randomized and 28 were followed-up for 12 months (conversion group, Group 1 =15 and control group, Group 2 =13). RT-PCR HCV levels reported in log values were comparable in both groups and among patients in the same group. The statistical analysis showed no interaction effect between time and group (p value G*M= 0.852), overtime intra-groups (p-value M=0.889) and between group (p-value G=0.286). Group 1 showed a higher incidence of dyslipidemia (p=0.03) and proteinuria events (p=0.01), while no difference was observed in the incidence of anemia (p=0.17), new onset of post-transplant diabetes mellitus (p=1.00) or urinary tract infection (p=0.60). The mean eGFR was similar in both groups. Conclusion: Our study did not show viral load decrease after conversion to EVR with maintenance of antiproliferative therapy. Currently, there is no specific immunosuppressive protocol for hepatitis C (HCV)-positive renal transplants recipients. Thus, the aim of this study was to evaluate the conversion effect to everolimus (EVR) on HCV in adult kidney recipients. This is an exploratory single-center, prospective, randomized, open label controlled trial with renal allograft recipients with HCV-positive serology. Participants were randomized for conversion to EVR or maintenance of calcineurin inhibitors. Thirty patients were randomized and 28 were followed-up for 12 months (conversion group, Group 1 =15 and control group, Group 2 =13). RT-PCR HCV levels reported in log values were comparable in both groups and among patients in the same group. The statistical analysis showed no interaction effect between time and group (p value G*M= 0.852), overtime intra-groups (p-value M=0.889) and between group (p-value G=0.286). Group 1 showed a higher incidence of dyslipidemia (p=0.03) and proteinuria events (p=0.01), while no difference was observed in the incidence of anemia (p=0.17), new onset of post-transplant diabetes mellitus (p=1.00) or urinary tract infection (p=0.60). The mean eGFR was similar in both groups. Our study did not show viral load decrease after conversion to EVR with maintenance of antiproliferative therapy. ABSTRACT Introduction: Currently, there is no specific immunosuppressive protocol for hepatitis C (HCV)-positive renal transplants recipients. Thus, the aim of this study was to evaluate the conversion effect to everolimus (EVR) on HCV in adult kidney recipients. Method: This is an exploratory single-center, prospective, randomized, open label controlled trial with renal allograft recipients with HCV-positive serology. Participants were randomized for conversion to EVR or maintenance of calcineurin inhibitors. Results: Thirty patients were randomized and 28 were followed-up for 12 months (conversion group, Group 1 =15 and control group, Group 2 =13). RT-PCR HCV levels reported in log values were comparable in both groups and among patients in the same group. The statistical analysis showed no interaction effect between time and group (p value G*M= 0.852), overtime intra-groups (p-value M=0.889) and between group (p-value G=0.286). Group 1 showed a higher incidence of dyslipidemia (p=0.03) and proteinuria events (p=0.01), while no difference was observed in the incidence of anemia (p=0.17), new onset of post-transplant diabetes mellitus (p=1.00) or urinary tract infection (p=0.60). The mean eGFR was similar in both groups. Conclusion: Our study did not show viral load decrease after conversion to EVR with maintenance of antiproliferative therapy. RESUMO Introdução: Atualmente não há um protocolo imunossupressor específico para os receptores de transplantes renais portadores de hepatite C (HCV). Assim, o objetivo deste estudo foi avaliar o efeito da conversão a Everolimo (EVR) na HCV em receptores adultos de transplantes renais. Método: Trata-se de um estudo unicêntrico, prospectivo, randomizado, exploratório, controlado, aberto em receptores de aloenxertos renais com sorologia positiva para HCV. Os participantes foram randomizados para conversão a EVR ou manutenção dos inibidores da calcineurina. Resultados: Trinta pacientes foram randomizados e 28 foram acompanhados por um período de 12 meses (grupo de conversão, Grupo 1 = 15 e grupo controle, Grupo 2 =13). Níveis de RT-PCR HCV descritos em valores logarítmicos foram comparáveis entre os grupos e entre pacientes em um mesmo grupo. A análise estatística não mostrou efeitos de interação entre tempo e grupo (valor p G*M= 0,852), ao longo do tempo em cada grupo (valor p M=0,889) e entre grupos (valor p G=0,286). O Grupo 1 apresentou uma maior incidência de eventos de dislipidemia (p=0,03) e proteinúria (p=0,01); não houve diferença na incidência de anemia (p=0,17), diabetes mellitus de início pós-transplante (p=1,00) ou infecção do trato urinário (p=0,60). A TFGe média foi semelhante nos dois grupos. Conclusão: Nosso estudo não mostrou redução da carga viral após conversão a EVR com manutenção do tratamento antiproliferativo. |
| Author | Garcia, Valter Duro Cardoso, Bruna Doleys Keitel, Elizete Neumann, Jorge Pacheco, Larissa Sgaria Prá, Ronivan Luis Dal Gnatta, Diego Rodrigues, Mariana Ferras Zanetti, Helen Kris Meinerz, Gisele |
| AuthorAffiliation | 1 Santa Casa de Misericórdia de Porto Alegre, Departamento de Nefrologia e Transplante de Rim, Porto Alegre, RS, Brasil 2 Universidade Federal de Ciências da Saúde de Porto Alegre, Programa de Pós-Graduação em Patologia, Porto Alegre, RS, Brasil |
| AuthorAffiliation_xml | – name: 1 Santa Casa de Misericórdia de Porto Alegre, Departamento de Nefrologia e Transplante de Rim, Porto Alegre, RS, Brasil – name: 2 Universidade Federal de Ciências da Saúde de Porto Alegre, Programa de Pós-Graduação em Patologia, Porto Alegre, RS, Brasil |
| Author_xml | – sequence: 1 givenname: Larissa Sgaria surname: Pacheco fullname: Pacheco, Larissa Sgaria organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Programa de Pós-Graduação em Patologia, Porto Alegre, RS, Brasil – sequence: 2 givenname: Valter Duro surname: Garcia fullname: Garcia, Valter Duro organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Programa de Pós-Graduação em Patologia, Porto Alegre, RS, Brasil – sequence: 3 givenname: Ronivan Luis Dal surname: Prá fullname: Prá, Ronivan Luis Dal organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Programa de Pós-Graduação em Patologia, Porto Alegre, RS, Brasil – sequence: 4 givenname: Bruna Doleys surname: Cardoso fullname: Cardoso, Bruna Doleys organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Programa de Pós-Graduação em Patologia, Porto Alegre, RS, Brasil – sequence: 5 givenname: Mariana Ferras surname: Rodrigues fullname: Rodrigues, Mariana Ferras organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Programa de Pós-Graduação em Patologia, Porto Alegre, RS, Brasil – sequence: 6 givenname: Helen Kris surname: Zanetti fullname: Zanetti, Helen Kris organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Programa de Pós-Graduação em Patologia, Porto Alegre, RS, Brasil – sequence: 7 givenname: Gisele surname: Meinerz fullname: Meinerz, Gisele organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Programa de Pós-Graduação em Patologia, Porto Alegre, RS, Brasil – sequence: 8 givenname: Jorge surname: Neumann fullname: Neumann, Jorge organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Programa de Pós-Graduação em Patologia, Porto Alegre, RS, Brasil – sequence: 9 givenname: Diego surname: Gnatta fullname: Gnatta, Diego organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Programa de Pós-Graduação em Patologia, Porto Alegre, RS, Brasil – sequence: 10 givenname: Elizete surname: Keitel fullname: Keitel, Elizete organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Programa de Pós-Graduação em Patologia, Porto Alegre, RS, Brasil |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29771270$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkc1u1DAURi1URIfSF2CB_AKh_omTeIMEo0KLKtjA2nLs684tiT2yPSNVvDyZDozoytL1950r-7wmZzFFIOQtZ--50uxK8F41g5C6-frpWyOHjr0gq9PwjKwYZ7wRA2Pn5LIUHJlkXLf9IF-Rc6H7nouercjv6xDAVZoCdSnuIRdMkYacZurs5DDCLmOkGDc4Yk250JooLLk04bwrdAlvYGsrVix0TfeYYUa75Kn1u6nSX-gjPNKabSzbycZKMzjcIsRa3pCXwU4FLv-eF-Tn5-sf65vm7vuX2_XHu8a1PWdNy4TnnWZcQN8rrsELxbnyQvvQjaoTyoESg3d-cGH5B-8U91x2VrfjIIOTF-T2yPXJPphtxtnmR5MsmqdByvfG5opuAtOOo2y9H1tg0LLgNQ9hWWm5lF1wT6wPR9Z2N87g3fKObKdn0Oc3ETfmPu1Np6TUA1sA4ghwOZWSIZy6nJmDWXOQaA4SzcMYzcHsUnr3_9ZT5Z9H-QcCm6Ul |
| CitedBy_id | crossref_primary_10_3389_fmed_2019_00020 crossref_primary_10_7759_cureus_27322 |
| Cites_doi | 10.1097/00007890-200109150-00019 10.1016/j.transproceed.2009.06.064 10.6002/ect.2013.0017 10.1097/TP.0b013e3181c7dcc0 10.1111/ajt.13620 10.1111/j.1600-6143.2010.03091.x 10.1097/TP.0b013e31824810e6 10.1016/j.intimp.2010.05.006 10.1038/474S1a 10.1128/JVI.78.7.3502-3513.2004 10.1016/S0041-1345(00)02682-8 10.1002/hep.26218 10.1097/TP.0000000000001618 10.1097/00007890-200107270-00013 10.1111/ajt.13518 10.1111/j.1399-0012.2012.01635.x 10.1111/ajt.12795 10.1016/j.intimp.2015.11.020 10.1158/1078-0432.CCR-13-3172 10.1097/TP.0b013e3182708e56 10.1128/JVI.79.14.8742-8749.2005 10.1111/j.1600-6143.2005.00864.x 10.1111/tid.12601 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 5PM DOA |
| DOI | 10.1590/2175-8239-JBN-3860 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
| DatabaseTitleList | MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2175-8239 |
| EndPage | 150 |
| ExternalDocumentID | oai_doaj_org_article_4bb34ddb4e0e40fd91ff519a1336fcfc 10_1590_2175_8239_jbn_3860 29771270 |
| Genre | Randomized Controlled Trial Journal Article |
| GroupedDBID | CGR CUY CVF ECM EIF NPM 2WC 53G 5VS AAYXX ABXHO ADBBV ALMA_UNASSIGNED_HOLDINGS AOIJS APOWU AZFZN BAWUL BCNDV CITATION DIK EMOBN F5P GROUPED_DOAJ GX1 HYE IPNFZ KQ8 OK1 PGMZT RIG RNS RPM RSC SCD SV3 5PM |
| ID | FETCH-LOGICAL-c4710-402d169012e77519ed25115d29df6b5625ce528dcd8cf860dc51d136a94b83fc3 |
| IEDL.DBID | RPM |
| ISSN | 0101-2800 2175-8239 |
| IngestDate | Tue Oct 22 15:09:51 EDT 2024 Tue Sep 17 21:23:36 EDT 2024 Fri Nov 22 07:16:59 EST 2024 Thu May 23 23:48:29 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4710-402d169012e77519ed25115d29df6b5625ce528dcd8cf860dc51d136a94b83fc3 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533980/ |
| PMID | 29771270 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_4bb34ddb4e0e40fd91ff519a1336fcfc pubmedcentral_primary_oai_pubmedcentral_nih_gov_6533980 crossref_primary_10_1590_2175_8239_jbn_3860 pubmed_primary_29771270 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-04-01 |
| PublicationDateYYYYMMDD | 2018-04-01 |
| PublicationDate_xml | – month: 04 year: 2018 text: 2018-04-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Brazil |
| PublicationPlace_xml | – name: Brazil |
| PublicationTitle | Brazilian Journal of Nephrology |
| PublicationTitleAlternate | J Bras Nefrol |
| PublicationYear | 2018 |
| Publisher | Sociedade Brasileira de Nefrologia |
| Publisher_xml | – name: Sociedade Brasileira de Nefrologia |
| References | Franciscus A (ref25) 2014 Nashan B (ref20) 2012; 93 Mannová P (ref22) 2005; 79 de Oliveira Uehara SN (ref23) 2012; 26 Andrassy J (ref15) 2012; 94 Gallego R (ref8) 2009; 41 Sindhi R (ref19) 2001; 72 Meinerz G (ref26) 2017; 17 Mas V (ref5) 2001; 33 Meier-Kriesche HU (ref3) 2001; 72 Razavi H (ref2) 2013; 57 Wowro SJ (ref17) 2016; 30 Coito C (ref21) 2004; 78 Kahraman A (ref6) 2011; 75 Wagner D (ref7) 2010; 10 Pascual J (ref24) 2016; 18 Kawada J (ref18) 2014; 21 Kamar N (ref13) 2016; 16 (ref1) 2011; 474 Fabrizi F (ref4) 2005; 5 Kucirka LM (ref10) 2010; 10 Lim WH (ref16) 2014; 14 Soliman A (ref14) 2013; 11 Di Benedetto F (ref9) 2010; 89 Lubetzky M (ref12) 2017; 101 Sawinski D (ref11) 2016; 16 |
| References_xml | – volume: 72 start-page: 851 year: 2001 ident: ref19 article-title: Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus publication-title: Transplantation doi: 10.1097/00007890-200109150-00019 contributor: fullname: Sindhi R – year: 2014 ident: ref25 contributor: fullname: Franciscus A – volume: 41 start-page: 2334 year: 2009 ident: ref8 article-title: Switching to sirolimus in renal transplant recipients with hepatitis C virus: a safe option publication-title: Transplant Proc doi: 10.1016/j.transproceed.2009.06.064 contributor: fullname: Gallego R – volume: 75 start-page: 16 year: 2011 ident: ref6 article-title: Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation publication-title: Clin Nephrol contributor: fullname: Kahraman A – volume: 11 start-page: 408 year: 2013 ident: ref14 article-title: Sirolimus conversion may suppress viral replication in hepatitis c virus-positive renal transplant candidates publication-title: Exp Clin Transplant doi: 10.6002/ect.2013.0017 contributor: fullname: Soliman A – volume: 89 start-page: 733 year: 2010 ident: ref9 article-title: First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation publication-title: Transplantation doi: 10.1097/TP.0b013e3181c7dcc0 contributor: fullname: Di Benedetto F – volume: 16 start-page: 1588 year: 2016 ident: ref11 article-title: Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents publication-title: Am J Transplant doi: 10.1111/ajt.13620 contributor: fullname: Sawinski D – volume: 10 start-page: 1238 year: 2010 ident: ref10 article-title: Under utilization of hepatitis C-positive kidneys for hepatitis C-positive recipients publication-title: Am J Transplant doi: 10.1111/j.1600-6143.2010.03091.x contributor: fullname: Kucirka LM – volume: 93 start-page: 1075 year: 2012 ident: ref20 article-title: Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients publication-title: Transplantation doi: 10.1097/TP.0b013e31824810e6 contributor: fullname: Nashan B – volume: 10 start-page: 990 year: 2010 ident: ref7 article-title: Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2010.05.006 contributor: fullname: Wagner D – volume: 474 start-page: S1 year: 2011 ident: ref1 article-title: Hepatitis C publication-title: Nature doi: 10.1038/474S1a – volume: 78 start-page: 3502 year: 2004 ident: ref21 article-title: High-throughput screening of the yeast kinome: identification of human serine/threonine protein kinases that phosphorylate the hepatitis C virus NS5A protein publication-title: J Virol doi: 10.1128/JVI.78.7.3502-3513.2004 contributor: fullname: Coito C – volume: 33 start-page: 1791 year: 2001 ident: ref5 article-title: Hepatitis C virus infection after renal transplantation: viral load and outcome publication-title: Transplant Proc doi: 10.1016/S0041-1345(00)02682-8 contributor: fullname: Mas V – volume: 57 start-page: 2164 year: 2013 ident: ref2 article-title: Chronic hepatitis C virus (HCV) disease burden and cost in the United States publication-title: Hepatology doi: 10.1002/hep.26218 contributor: fullname: Razavi H – volume: 101 start-page: 1704 year: 2017 ident: ref12 article-title: Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients With Directly Acting Antiviral Agents publication-title: Transplantation doi: 10.1097/TP.0000000000001618 contributor: fullname: Lubetzky M – volume: 72 start-page: 241 year: 2001 ident: ref3 article-title: Hepatitis C antibody status and outcomes in renal transplant recipients publication-title: Transplantation doi: 10.1097/00007890-200107270-00013 contributor: fullname: Meier-Kriesche HU – volume: 16 start-page: 1474 year: 2016 ident: ref13 article-title: Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation publication-title: Am J Transplant doi: 10.1111/ajt.13518 contributor: fullname: Kamar N – volume: 26 start-page: 842 year: 2012 ident: ref23 article-title: Histological evoluation of hepatitis C virus infection after renal transplantation publication-title: Clin Transplant doi: 10.1111/j.1399-0012.2012.01635.x contributor: fullname: de Oliveira Uehara SN – volume: 14 start-page: 2106 year: 2014 ident: ref16 article-title: A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients publication-title: Am J Transplant doi: 10.1111/ajt.12795 contributor: fullname: Lim WH – volume: 30 start-page: 9 year: 2016 ident: ref17 article-title: Effects of mTOR and calcineurin inhibitor combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2015.11.020 contributor: fullname: Wowro SJ – volume: 21 start-page: 5412 year: 2014 ident: ref18 article-title: mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-3172 contributor: fullname: Kawada J – volume: 94 start-page: 1208 year: 2012 ident: ref15 article-title: Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis publication-title: Transplantation doi: 10.1097/TP.0b013e3182708e56 contributor: fullname: Andrassy J – volume: 79 start-page: 8742 year: 2005 ident: ref22 article-title: Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication publication-title: J Virol doi: 10.1128/JVI.79.14.8742-8749.2005 contributor: fullname: Mannová P – volume: 5 start-page: 1452 year: 2005 ident: ref4 article-title: Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies publication-title: Am J Transplant doi: 10.1111/j.1600-6143.2005.00864.x contributor: fullname: Fabrizi F – volume: 18 start-page: 819 year: 2016 ident: ref24 article-title: Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients publication-title: Transpl Infect Dis doi: 10.1111/tid.12601 contributor: fullname: Pascual J – volume: 17 year: 2017 ident: ref26 article-title: Center Initial Experience in Treating Chronic Hepatitis C in Kidney Transplant Recipients publication-title: Am J Transplant contributor: fullname: Meinerz G |
| SSID | ssib030194783 ssj0000390488 |
| Score | 2.114388 |
| Snippet | Currently, there is no specific immunosuppressive protocol for hepatitis C (HCV)-positive renal transplants recipients. Thus, the aim of this study was to... ABSTRACT Introduction: Currently, there is no specific immunosuppressive protocol for hepatitis C (HCV)-positive renal transplants recipients. Thus, the aim of... |
| SourceID | doaj pubmedcentral crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 143 |
| SubjectTerms | Adult Calcineurin Inhibitors - therapeutic use Carga Viral Everolimus - therapeutic use Female Hepatite C Hepatitis C, Chronic - drug therapy Humans Immunosuppressive Agents - therapeutic use Imunossupressão Kidney Transplantation Male Original Postoperative Complications - drug therapy Postoperative Complications - virology Prospective Studies Transplante Renal Viremia - drug therapy |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07T8MwELaAiQWBeJWXPLChqE7iPDzyaNWJBZDYIttnq4E2RbRFQvx57pxS2omF1Tkl1ueL785395mxS6E0OkOQRc5ZE0mX60jHwuB_JZSREtAoUHPy4KG4fy7vekSTs7zqi2rCWnrgFriuNCaVAEY64aTwoGLv0evQGFvl3nobdl-RrwRTqEmotUoWgYMTXe4sKpNULTpmMiW6y7HoxTRRWgZ-yl-rFMj7VyzSerXkivnp77Kdhd_Ir9v57rEN1-yzr5Z7mE88D9Xj4eiLU8cIR-gpZU5n6bxuhrWp6VodPptwh3KTUT2eTzkKDx2VVM_qKb_lH7j9jWuN8jzQcvDXGhr3yWeBAH2Ea8CJC-ONWiinB-yp33u8HUSL2xQiiwZIUKAIlBOLE1cUiKADii4ySBT43FAcZF2WlEBkAR4hAZvFEKe5VtKUqbfpIdtqJo07ZtwamWqjvQCnpVZGk6WNtbSgdQpl0WFXP2hWby1pRkXBBmJfEfYVYV8h9hVh32E3BPhSkgivwwCqQbVQg-ovNeiwo3aVlq9J0LOltHqHFWvrt_ad9SdNPQwE2zn6wKoUJ_8xsVO2jT5W2Rb7nLGt2fvcnbPNKcwvgsp-A-sI9ak priority: 102 providerName: Directory of Open Access Journals |
| Title | Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29771270 https://pubmed.ncbi.nlm.nih.gov/PMC6533980 https://doaj.org/article/4bb34ddb4e0e40fd91ff519a1336fcfc |
| Volume | 40 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELboHhAXxJuyUPnADXnrJM7DR7Z0tYC6QgIkbpGf1NAm1bZdCfHnmXGS1ebKJYdmmqT-pplv7JnPhLzlUgEZsjlzzmgmXKGYSriG_xWXWggLQQGbky-_llc_qg9LlMnJh16YWLRvdDhrNtuzJqxjbeVua-ZDndj8y2pRAEeRFZ9PyAS44ThFB4eVYliaiq9jyOpF3H8S5dRYCgypb57JJZ8DI89ZlWaSfTq_YllV4NZwKZAiXJEdxaoo6X8nTo1rKO8EpYtH5GHPJun77qkfk3uueULur_r18qfkbydOTFtPY3l5nBuj2FJCARu0wcl2Gpp10AH33aGHljqwazdhe9xTMF47rLk-hD1d0Bt4P26DAnsadTvo72Ab94ceokL6BkCiKJaxwx7L_TPy_WL5bXHJ-u0WmIEIxTGTtLholqSuLIHYOYvpR25TaX2hMVEyLk8ri2oCHgbKmjyxSVYoKXSVeZM9JydN27iXhBotMqWV59YpoaRWGIoTJYxVKrNVOSXvhoGtd52qRo3ZCCBSIyI1IlL_0k2NiEzJOY79rSUqYscP2uufde8XtdA6E9Zq4bgT3FuZeA8_QkEOXnjjzZS86AC7vcyA8pSUIyhH9xmfAYeMCty9A77672-ekgfAvKquBOg1OTlcH90bMtnb4wx4_cfPszg3AMflYjWL_v0P7Az9qg |
| link.rule.ids | 230,315,729,782,786,866,887,2106,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZokYAL5c3SAj5wQ-46ifPwkW5bLdBdIVEkbpGf3cBusuruIiH-PDNOUjXXXuNxIuezPTOemc-EfOBSgTFkU-ac0Uy4TDEVcQ3riksthAWlgMXJ0-_5_GdxeoY0OWlfCxOS9o2ujuvl6riuFiG3cr0y4z5PbPxtNsnARpEFH--R-7BeOR866TBlpeiDU2FDBr9ehBsokVCNxdCjK59JJR-DTZ6yIk4k-3IyZ0mR4eVwMZhFGJMdaKtA6n9LUw2zKG-ppfODOw7oCXnc2aH0U9v8lNxz9TPyYNZF2p-Tfy2tMW08DYnp4VSNYjEKBVRRBo_paVUvKl3hjT1021AHcs2yWu02FIQXDrO1t9WGTugf2FlXlQJ5Ghg_6O_K1u4v3QZu9SXAS5FmY43VmZsX5Mf52eVkyrqLGpgB3cbRB7UYbotil-dgEjqLjktqY2l9ptHFMi6NC4s8BB5-sDVpZKMkU1LoIvEmeUn266Z2rwk1WiRKK8-tU0JJrVCJR0oYq1Rii3xEPvaAlOuWj6NEPwaQLBHJEpEsf-m6RCRH5AQxu5FELu3woLm-KjsASqF1IqzVwnEnuLcy8h4GocB7z7zxZkRetUDfvKafHSOSD6bA4DvDFkA-cHd3SL-5c8_35OH0cnZRXnyefz0kj8B-K9pEoiOyv73eubdkb2N378KK-A9iQhBf |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZokSouUN5LW_CBG3LjJM7DR7rtqjy6qgRI3CI_u4HdZNXdRUL8eWac7Kq5wjWZJHI-2zPjmfmGkLdcKjCGbMacM5oJlyumYq5hXXGphbCgFLA4-fJLMf1enl8gTc6u1VdI2je6Pm3mi9OmnoXcyuXCRNs8sej6apyDjSJLHi2tj_bIfVizPBk66jBtpdgGqMKmDL69CF0okVSNJWAn9SU0meQR2OUZK5NUso9nU5aWOTaIS8A0wrjsQGMFYv872mqYSXlHNU0e_cegDsnD3h6l7zuRx-Sea56Qg6s-4v6U_OnojWnraUhQD6drFItSKKCLMnhcT-tmVusaO_fQdUsdyLXzerFZURCeOczaXtcrOqa_YIdd1ArkaWD-oD9r27jfdB041ucAM0W6jSVWaa6ekW-Ti6_jS9Y3bGAGdBxHX9Ri2C1OXFGAaegsOjCZTaT1uUZXy7gsKS3yEXj4ydZksY3TXEmhy9Sb9DnZb9rGvSTUaJEqrTy3TgkltUJlHithrFKpLYsRebcFpVp2vBwV-jOAZoVoVohm9UM3FaI5ImeI204SObXDhfb2pupBqITWqbBWC8ed4N7K2HsYhAIvPvfGmxF50YG9e812hoxIMZgGg-8M7wD6gcO7R_vVPz_5hhxcn0-qzx-mn47IAzDjyi6f6Jjsr2837oTsrezmdVgUfwHeuhLf |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+conversion+from+calcineurin+inhibitors+to+everolimus+on+hepatitis+C+viremia+in+adult+kidney+transplant+recipients&rft.jtitle=Jornal+Brasileiro+de+nefrologia&rft.au=Pacheco%2C+Larissa+Sgaria&rft.au=Garcia%2C+Valter+Duro&rft.au=Pr%C3%A1%2C+Ronivan+Luis+Dal&rft.au=Cardoso%2C+Bruna+Doleys&rft.date=2018-04-01&rft.pub=Sociedade+Brasileira+de+Nefrologia&rft.issn=0101-2800&rft.eissn=2175-8239&rft.volume=40&rft.issue=2&rft.spage=143&rft.epage=150&rft_id=info:doi/10.1590%2F2175-8239-JBN-3860&rft_id=info%3Apmid%2F29771270&rft.externalDBID=PMC6533980 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0101-2800&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0101-2800&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0101-2800&client=summon |